These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 33725335)
21. Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch? Danan G; Teschke R Drug Saf; 2018 Aug; 41(8):735-743. PubMed ID: 29502198 [TBL] [Abstract][Full Text] [Related]
22. A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development. Hermann RP; Rockey DC; Suzuki A; Merz M; Tillmann HL Aliment Pharmacol Ther; 2022 Apr; 55(8):1028-1037. PubMed ID: 35266155 [TBL] [Abstract][Full Text] [Related]
23. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method. Teschke R Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1169-1187. PubMed ID: 30354694 [TBL] [Abstract][Full Text] [Related]
24. Value of liver biopsy in the diagnosis of drug-induced liver injury. Ahmad J; Barnhart HX; Bonacini M; Ghabril M; Hayashi PH; Odin JA; Rockey DC; Rossi S; Serrano J; Tillmann HL; Kleiner DE; J Hepatol; 2022 May; 76(5):1070-1078. PubMed ID: 35074471 [TBL] [Abstract][Full Text] [Related]
25. Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment. Mullins C; Beaulac K; Sylvia L Ann Pharmacother; 2020 Jun; 54(6):526-532. PubMed ID: 31786964 [No Abstract] [Full Text] [Related]
26. Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019. Teschke R Front Pharmacol; 2019; 10():730. PubMed ID: 31396080 [TBL] [Abstract][Full Text] [Related]
27. Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Hussaini SH; Farrington EA Expert Opin Drug Saf; 2014 Jan; 13(1):67-81. PubMed ID: 24073714 [TBL] [Abstract][Full Text] [Related]
28. Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use. Marquez L; Raheja R; Chan-Liston M; Marcinak J; Estilo A; Pineda Salgado L; Jiang J; Chang C; Beninger P Drug Saf; 2024 Jan; 47(1):1-22. PubMed ID: 37874451 [TBL] [Abstract][Full Text] [Related]
29. A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT). Tillmann HL; Suzuki A; Merz M; Hermann R; Rockey DC PLoS One; 2022; 17(9):e0271304. PubMed ID: 36174069 [TBL] [Abstract][Full Text] [Related]
30. Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method. Teschke R; Méndez-Sánchez N; Eickhoff A Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563242 [TBL] [Abstract][Full Text] [Related]
31. Agreement Among Different Scales for Causality Assessment in Drug-Induced Liver Injury. Das S; Behera SK; Xavier AS; Velupula S; Dkhar SA; Selvarajan S Clin Drug Investig; 2018 Mar; 38(3):211-218. PubMed ID: 29185238 [TBL] [Abstract][Full Text] [Related]
33. Utility of a Computerized ICD-10 Algorithm to Identify Idiosyncratic Drug-Induced Liver Injury Cases in the Electronic Medical Record. Yeboah-Korang A; Louissaint J; Tsung I; Prabhu S; Fontana RJ Drug Saf; 2020 Apr; 43(4):371-377. PubMed ID: 31916081 [TBL] [Abstract][Full Text] [Related]
34. Drug-Induced Liver Injury during Consolidation Therapy in Childhood Acute Lymphoblastic Leukemia as Assessed for Causality Using the Updated RUCAM. Qin FL; Sang GY; Zou XQ; Cheng DH Can J Gastroenterol Hepatol; 2022; 2022():5914593. PubMed ID: 35369115 [TBL] [Abstract][Full Text] [Related]
35. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. Regev A; Avigan MI; Kiazand A; Vierling JM; Lewis JH; Omokaro SO; Di Bisceglie AM; Fontana RJ; Bonkovsky HL; Freston JW; Uetrecht JP; Miller ED; Pehlivanov ND; Haque SA; Harrison MJ; Kullak-Ublick GA; Li H; Patel NN; Patwardhan M; Price KD; Watkins PB; Chalasani NP J Autoimmun; 2020 Nov; 114():102514. PubMed ID: 32768244 [TBL] [Abstract][Full Text] [Related]
36. Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. Clinton JW; Kiparizoska S; Aggarwal S; Woo S; Davis W; Lewis JH Drug Saf; 2021 Nov; 44(11):1125-1149. PubMed ID: 34533782 [TBL] [Abstract][Full Text] [Related]
37. Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. Teschke R; Wolff A; Frenzel C; Schwarzenboeck A; Schulze J; Eickhoff A World J Hepatol; 2014 Jan; 6(1):17-32. PubMed ID: 24653791 [TBL] [Abstract][Full Text] [Related]
38. Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use. Teschke R; Danan G Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446036 [TBL] [Abstract][Full Text] [Related]
39. Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative. Cohen EB; Patwardhan M; Raheja R; Alpers DH; Andrade RJ; Avigan MI; Lewis JH; Rockey DC; Chui F; Iacob AM; Linardi CC; Regev A; Shick J; Lucena MI Drug Saf; 2024 Apr; 47(4):301-319. PubMed ID: 38217833 [TBL] [Abstract][Full Text] [Related]
40. A revised electronic version of RUCAM for the diagnosis of DILI. Hayashi PH; Lucena MI; Fontana RJ; Bjornsson ES; Aithal GP; Barnhart H; Gonzalez-Jimenez A; Yang Q; Gu J; Andrade RJ; Hoofnagle JH Hepatology; 2022 Jul; 76(1):18-31. PubMed ID: 35014066 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]